

À des fins de recherche uniquement

Anticorps Polyclonal de lapin anti-FABP4

Numéro de catalogue: **15872-1-AP** 11 Publications



Informations de base

Numéro de catalogue:	BC003672	Méthode de purification:
15872-1-AP		Purification par affinité contre l'antigène
Taille:	2167	Dilutions recommandées:
150ul , Concentration: 500 µg/ml by Nanodrop and 267 µg/ml by Bradford method using BSA as the standard;	fatty acid binding protein 4, adipocyte	WB 1:500-1:1000 IHC 1:20-1:200 IF 1:20-1:200
Hôte:	MW calculé	
Lapin	132 aa, 15 kDa	
Isotype:	MW observés:	
IgG	15 kDa	
Immunogen Catalog Number:		
AG8631		

Applications

Applications testées:	Contrôles positifs:
IF, IHC, WB,ELISA	WB : tissu de muscle squelettique de rat, tissu de muscle squelettique de souris
Demandes citées:	IHC : tissu de col de l'utérus humain, tissu cutané humain
IF, IHC, WB	IF : tissu adipeux de souris, cellules HUVEC
Spécificité de l'espèce:	
Humain, rat, souris	
Espèces citées:	
Humain, rat, souris	

Remarque-IHC: il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9,0; (*) À défaut, 'le démasquage de l'antigène peut être effectué avec un tampon citrate pH 6,0.

Informations générales

Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFkB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.

Publications notables

Autrice	Pubmed ID	Journal	Application
Marion Claudia Salzer	30415840	Cell	IF
Xin Peng	35646835	Front Bioeng Biotechnol	WB
J Zhou	25817070	Int J Obes (Lond)	WB

Stockage

Stockage:

Stocker à -20°C. Stable pendant un an après l'expédition.

Tampon de stockage:

PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3


L'aliquotage n'est pas nécessaire pour le stockage à -20°C

*** Les 20ul contiennent 0,1% de BSA.


For technical support and original validation data for this product please contact:
T: 1(888) 4PTGLAB (1-888-478-4522) (toll free in USA), or 1(312) 455-8498 (outside USA)
E: proteintech@ptglab.com
W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


Données de validation sélectionnées




rat skeletal muscle tissue were subjected to SDS PAGE followed by western blot with 15872-1-AP (FABP4 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.



IF result of anti-FABP4 (15872-1-AP, 1:500) with PFA fixed mouse adipose tissue by Dr. Daniel Kopinke.



Immunohistochemical analysis of paraffin-embedded human cervix using 15872-1-AP (FABP4 antibody) at dilution of 1:50 (under 10x lens).



Immunohistochemical analysis of paraffin-embedded human cervix using 15872-1-AP (FABP4 antibody) at dilution of 1:50 (under 40x lens).